Nitric oxide for cancer therapy

Sergio Huerta

doi:10.4155/fso.15.44

Nitric oxide for cancer therapy

Sergio Huerta

Research output: Contribution to journal › Review article › peer-review

64 Scopus citations

Abstract

Resistance to current therapeutic interventions is a major challenge in the treatment of patients affected by cancer. While nitric oxide (NO) might have proneoplastic properties, it is now clear that at high doses, NO has a role in cancer therapeutics. Either as a single agent or in combination with other antineoplastic compounds, NO might be used to overcome tumor cell resistance to conventional treatments. The following discussion addresses the role of NO in cancer therapeutics and includes a report on the role of NO donors in the area of cancer therapeutics.

Original language	English (US)
Article number	FSO44
Journal	Future Science OA
Volume	1
Issue number	1
DOIs	https://doi.org/10.4155/fso.15.44
State	Published - Aug 2015
Externally published	Yes

Keywords

JSK
NO donors
NO hybrids
diazeniumdiolates

ASJC Scopus subject areas

Biotechnology

Access to Document

10.4155/fso.15.44

Cite this

@article{ccbf5326bf8d477e989c0f22ee88f8ba,

title = "Nitric oxide for cancer therapy",

abstract = "Resistance to current therapeutic interventions is a major challenge in the treatment of patients affected by cancer. While nitric oxide (NO) might have proneoplastic properties, it is now clear that at high doses, NO has a role in cancer therapeutics. Either as a single agent or in combination with other antineoplastic compounds, NO might be used to overcome tumor cell resistance to conventional treatments. The following discussion addresses the role of NO in cancer therapeutics and includes a report on the role of NO donors in the area of cancer therapeutics.",

keywords = "JSK, NO donors, NO hybrids, diazeniumdiolates",

author = "Sergio Huerta",

note = "Publisher Copyright: {\textcopyright} 2015 S Huerta.",

year = "2015",

month = aug,

doi = "10.4155/fso.15.44",

language = "English (US)",

volume = "1",

journal = "Future Science OA",

issn = "2056-5623",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Nitric oxide for cancer therapy

AU - Huerta, Sergio

PY - 2015/8

Y1 - 2015/8

N2 - Resistance to current therapeutic interventions is a major challenge in the treatment of patients affected by cancer. While nitric oxide (NO) might have proneoplastic properties, it is now clear that at high doses, NO has a role in cancer therapeutics. Either as a single agent or in combination with other antineoplastic compounds, NO might be used to overcome tumor cell resistance to conventional treatments. The following discussion addresses the role of NO in cancer therapeutics and includes a report on the role of NO donors in the area of cancer therapeutics.

AB - Resistance to current therapeutic interventions is a major challenge in the treatment of patients affected by cancer. While nitric oxide (NO) might have proneoplastic properties, it is now clear that at high doses, NO has a role in cancer therapeutics. Either as a single agent or in combination with other antineoplastic compounds, NO might be used to overcome tumor cell resistance to conventional treatments. The following discussion addresses the role of NO in cancer therapeutics and includes a report on the role of NO donors in the area of cancer therapeutics.

KW - JSK

KW - NO donors

KW - NO hybrids

KW - diazeniumdiolates

UR - http://www.scopus.com/inward/record.url?scp=85027229761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027229761&partnerID=8YFLogxK

U2 - 10.4155/fso.15.44

DO - 10.4155/fso.15.44

M3 - Review article

C2 - 28031862

AN - SCOPUS:85027229761

SN - 2056-5623

VL - 1

JO - Future Science OA

JF - Future Science OA

IS - 1

M1 - FSO44

ER -

Nitric oxide for cancer therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this